Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Average Rating of “Buy” from Analysts

Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) have been assigned a consensus rating of “Buy” from the seven brokerages that are covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and two have given a strong buy rating to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $27.80.

A number of equities research analysts have commented on TBPH shares. Wall Street Zen cut shares of Theravance Biopharma from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 3rd. HC Wainwright raised their price objective on shares of Theravance Biopharma from $15.00 to $20.00 and gave the company a “buy” rating in a research report on Tuesday, November 11th. Weiss Ratings restated a “hold (c)” rating on shares of Theravance Biopharma in a research note on Thursday, January 22nd. BTIG Research reiterated a “buy” rating and issued a $40.00 price target on shares of Theravance Biopharma in a research note on Tuesday, February 3rd. Finally, Oppenheimer began coverage on Theravance Biopharma in a report on Wednesday, December 3rd. They set an “outperform” rating and a $27.00 price target on the stock.

Insider Buying and Selling

In related news, SVP Rhonda Farnum sold 31,067 shares of the business’s stock in a transaction that occurred on Wednesday, December 3rd. The stock was sold at an average price of $18.75, for a total value of $582,506.25. Following the transaction, the senior vice president directly owned 277,695 shares of the company’s stock, valued at approximately $5,206,781.25. The trade was a 10.06% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 6.90% of the company’s stock.

Institutional Investors Weigh In On Theravance Biopharma

Several institutional investors and hedge funds have recently modified their holdings of the stock. Inspire Investing LLC purchased a new stake in Theravance Biopharma during the third quarter valued at approximately $1,074,000. Assenagon Asset Management S.A. increased its position in shares of Theravance Biopharma by 1,629.4% during the 3rd quarter. Assenagon Asset Management S.A. now owns 414,715 shares of the biopharmaceutical company’s stock valued at $6,055,000 after purchasing an additional 390,735 shares during the last quarter. Acadian Asset Management LLC raised its holdings in Theravance Biopharma by 76.8% during the 2nd quarter. Acadian Asset Management LLC now owns 308,652 shares of the biopharmaceutical company’s stock valued at $3,401,000 after buying an additional 134,058 shares during the period. Jefferies Financial Group Inc. raised its holdings in Theravance Biopharma by 1,191.9% during the 2nd quarter. Jefferies Financial Group Inc. now owns 276,887 shares of the biopharmaceutical company’s stock valued at $3,054,000 after buying an additional 255,455 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new stake in Theravance Biopharma in the second quarter worth $624,000. Institutional investors own 99.10% of the company’s stock.

Theravance Biopharma Stock Performance

NASDAQ:TBPH opened at $20.48 on Monday. The stock has a 50-day simple moving average of $19.07 and a two-hundred day simple moving average of $15.99. The firm has a market capitalization of $1.04 billion, a PE ratio of 35.93 and a beta of 0.15. Theravance Biopharma has a 52-week low of $7.90 and a 52-week high of $21.03.

Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings data on Monday, November 10th. The biopharmaceutical company reported $0.07 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.10. The firm had revenue of $19.99 million for the quarter, compared to analysts’ expectations of $19.89 million. Theravance Biopharma had a return on equity of 12.20% and a net margin of 36.53%. Equities analysts forecast that Theravance Biopharma will post -1.09 earnings per share for the current fiscal year.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.